Results 181 to 190 of about 37,073 (238)

Persistent FGFR pathway dependence: where does tinengotinib fit after FGFR inhibitor therapy in advanced cholangiocarcinoma? [PDF]

J Gastrointest Oncol
Sasanuma H, Yamaguchi H.
europepmc   +1 more source

FGFR2 Gene Rearrangement [PDF]

, 2020
openaire   +1 more source

Discovery and validation of a multi-protein panel for predicting non-fatal major adverse cardiovascular events in diabetic kidney disease. [PDF]

Front Endocrinol (Lausanne)
Jiang L, Chien C, Li T, Zhang H, Zhao T, Wu X.   +5 more
europepmc   +1 more source

<i>FGF18</i> aggravates angiotensin II-induced vascular smooth muscle cell dysfunction via the FGFR-ERK/AKT-GSK3β/β-catenin pathway. [PDF]

J Thorac Dis
He Y, Chen T, Xiang Y, Li D, Zhang H, Wu Z, He Y.   +6 more
europepmc   +1 more source

Structure-Based Design and Optimization of Novel, Potent and Selective Covalent FGFR2/3 Inhibitors with a Tricyclic Core. [PDF]

J Med Chem
Lu X, Tian Z, Li X, Chen X, Tien JC, Yang Y, Yin Y, Li Q, Huang W, Zhou F, Zhang J, Ren X, Liu D, Todd AJ, Li S, Chen Y, Chinnaiyan AM, Chang S, Ding K, Wang Z.   +19 more
europepmc   +1 more source

FGFR2b in Gastric Cancer: Translating a Therapeutic Target into a Reliable Biomarker. [PDF]

Cancers (Basel)
Satala CB, Gurău G, Patrichi G, Gurau AM, Mehedinti RC, Leibovici AR, Mihalache D.   +6 more
europepmc   +1 more source

DNA hypermethylation of FGFR2 drives fibrosis in the aging kidney. [PDF]

Sci Rep
Qian Y, Liu C, Cui M, Xu K, Liu S, Qi L, Jiao D, Zhao C.   +7 more
europepmc   +1 more source